ANGO

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,272

F4 · shares: The acquisition of 26,189 shares of Common Stock of the Company represents 26,189 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013933 · doc1.xml · nonDerivative · entry 1

Auen Eileen O'Shea · CIK 0001428073 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,401

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013927 · doc1.xml · nonDerivative · entry 1

Meteny Dennis S · CIK 0001289336 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,139

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013937 · doc1.xml · nonDerivative · entry 1

JOHNSON WESLEY · CIK 0001258791 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,649

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013914 · doc1.xml · derivative · entry 3

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,418

Underlying: Common Stock · 8,418 shares

Expires 2031-07-21

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013914 · doc1.xml · derivative · entry 2

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,197

Underlying: Common Stock · 6,197 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013914 · doc1.xml · nonDerivative · entry 1

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,098

F1 · shares: The acquisition of 3,098 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents 3,098 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013931 · doc1.xml · nonDerivative · entry 1

DONNELLY HOWARD W · CIK 0001212978 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,712

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013929 · doc1.xml · derivative · entry 6

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,128

Underlying: Common Stock · 20,128 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013929 · doc1.xml · derivative · entry 5

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,817

Underlying: Common Stock · 14,817 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 4

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,661

F4 · shares: The acquisition of 7,408 shares of Common Stock of the Company represents 7,408 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013925 · doc1.xml · derivative · entry 6

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

Underlying: Common Stock · 11,026 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013925 · doc1.xml · derivative · entry 5

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,116

Underlying: Common Stock · 8,116 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 4

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,822

F4 · shares: The acquisition of 4,058 shares of Common Stock of the Company represents 4,058 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013921 · doc1.xml · nonDerivative · entry 1

Licitra Karen A · CIK 0001754757 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,118

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-013920 · doc1.xml · derivative · entry 6

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,923

Underlying: Common Stock · 11,923 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013920 · doc1.xml · derivative · entry 5

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,777

Underlying: Common Stock · 8,777 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013920 · doc1.xml · nonDerivative · entry 4

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,979

F4 · shares: The acquisition of 4,388 shares of Common Stock of the Company represents 4,388 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013915 · doc1.xml · nonDerivative · entry 1

Tarnoff Michael E · CIK 0001603289 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,061

F1 · shares: The acquisition of 5,738 shares of common stock ("Common Stock") of AngioDynamics, Inc., represents 5,738 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. The restricted stock units vest on 07/21/2022.

SEC source: 0001567619-21-018541 · doc1.xml · derivative · entry 3

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,019

Underlying: Common Stock · 8,019 shares

Expires 2031-07-21

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-018541 · doc1.xml · derivative · entry 2

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,903

Underlying: Common Stock · 5,903 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-018541 · doc1.xml · nonDerivative · entry 1

Piccinini Laura · CIK 0001875140 · SVP International

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,952

F1 · date: The restricted stock units, performance rights and stock options set forth in this Form 4 were granted to the Reporting Person effective July 21, 2021. Due to an administrative error, the acquisition of the securities by the Reporting Person was delayed.

F2 · shares: The acquisition of 2,952 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 2,952 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022711 · doc1.xml · derivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,721

Underlying: Common Stock · 7,721 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022711 · doc1.xml · derivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,684

Underlying: Common Stock · 5,684 shares

Expires not disclosed

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-022713 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,667

Underlying: Common Stock · 101,667 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

F1 · derivative.underlying_shares: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F1 · balance_after: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

SEC source: 0001567619-21-022713 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,840

Underlying: Common Stock · 74,840 shares

Expires not disclosed

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.underlying_shares: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F1 · balance_after: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

SEC source: 0001567619-21-022713 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,503

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F2 · shares: The acquisition of 37,420 shares of common stock ("Common Stock") of the Company represents 37,420 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022705 · doc1.xml · derivative · entry 2

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,418

Underlying: Common Stock · 8,418 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022705 · doc1.xml · derivative · entry 1

ROSENZWEIG RICHARD C · CIK 0001206725 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,197

Underlying: Common Stock · 6,197 shares

Expires not disclosed

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of performance rights and stock options of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance rights and the exercise price of the options.

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock of the Company ("Common Stock"). The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-022716 · doc1.xml · derivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,026

Underlying: Common Stock · 11,026 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of stock options of AngioDynamics, Inc., which contained an administrative error as to the exercise price of such options.

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022709 · doc1.xml · derivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,923

Underlying: Common Stock · 11,923 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of stock options of AngioDynamics, Inc., which contained an administrative error as to the exercise price of such options.

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022707 · doc1.xml · derivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,128

Underlying: Common Stock · 20,128 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report, among other items, the granting of stock options of AngioDynamics, Inc., which contained an administrative error as to the exercise price of such options.

F2 · derivative.exercise_date: The exempt disposition of 354 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 3

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,821

F3 · shares: The exempt disposition of 344 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,083

F3 · shares: The exempt disposition of 1,483 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,253

F3 · shares: The exempt disposition of 400 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 3

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,764

F3 · shares: The exempt disposition of 417 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013920 · doc1.xml · nonDerivative · entry 3

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,591

F3 · shares: The exempt disposition of 300 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 2

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,165

F2 · shares: The exempt disposition of 339 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,566

F2 · shares: The exempt disposition of 2,131 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,653

F2 · shares: The exempt disposition of 354 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 2

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,181

F2 · shares: The exempt disposition of 294 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013920 · doc1.xml · nonDerivative · entry 2

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,891

F2 · shares: The exempt disposition of 262 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013923 · doc1.xml · nonDerivative · entry 1

Centea Scott · CIK 0001823973 · SVP/GM, VIT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,504

F1 · shares: The exempt disposition of 500 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,697

F1 · shares: The exempt disposition of 4,622 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-013929 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,007

F1 · shares: The exempt disposition of 1,284 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-013925 · doc1.xml · nonDerivative · entry 1

Helsel Dave · CIK 0001543753 · SVP Global Operations and R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,475

F1 · shares: The exempt disposition of 640 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-013920 · doc1.xml · nonDerivative · entry 1

Campbell Chad Thomas · CIK 0001706852 · SVP/GM, Vascular Access

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,153

F1 · shares: The exempt disposition of 571 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-21-008240 · doc1.xml · derivative · entry 3

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,625 shares

Expires 2021-07-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options for one-fourth of the shares became exercisable on 7/25/2015, 7/25/2016, 7/25/2017 and 7/25/2018, respectively.

SEC source: 0001567619-21-008240 · doc1.xml · nonDerivative · entry 2

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,291

F1 · shares: The disposition of 10,080 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. reflects a net exercise of options expiring on July 25, 2021, in which shares of Common Stock were disposed to satisfy the payment of the exercise price and tax withholding obligations.

SEC source: 0001567619-21-008240 · doc1.xml · nonDerivative · entry 1

Trowbridge Stephen A · CIK 0001624250 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.